Cardiogeni Plc

Director's Dealing • Aug 29, 2025

National Storage Mechanism | Additional information

RNS Number : 3264X

Cardiogeni PLC

29 August 2025

29 August 2025

Cardiogeni PLC

("Cardiogeni" or the "Company")

Director's Dealings

Cardiogeni (AQSE: CGNI), a UK clinical stage biotechnology company founded by 2007 Nobel Laureate Sir Martin Evans to advance novel heart failure medicines through human trials, announces that Ajan Reginald, Director of Cardiogeni has purchased a total of 12,001 ordinary shares of the Company, the details of which are set out in the notification below.

Following the purchase, Ajan Reginald's will hold 18,871,851 ordinary shares representing 22.11% of Cardiogeni's issued share capital.

The directors of Cardiogeni accept responsibility for this announcement.

This announcement, including the notification below, is made in accordance with the requirements of the UK Market Abuse Regulation.

For further information please contact:

Cardiogeni PLC
Dr Darrin M Disley OBE, Executive Chairman	Via First Sentinel
First Sentinel Corporate Finance Limited Corporate Adviser
Brian Stockbridge Gabrielle Cordeiro	+44 (0) 7858 888007

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.  

Details of the person discharging managerial responsibilities / person closely associated  

a) 

Name 

Ajan Reginald

Reason for the Notification  

a) 

Position/status 

Executive Chairman

b) 

Initial notification / Amendment 

Initial notification 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  

a) 

Name 

Cardiogeni PLC

b) 

LEI 

9845000F8F59ATZD8F92

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

a) 

Description of the Financial instrument, type of instrument 

Ordinary shares 

ISIN 

GB00BTBLFC12

b) 

Nature of the transaction 

Purchase of shares

c) 

Price(s) and volume(s) 

	Date	Price(s)	Volume(s)
1.	29-08-2025	£0.20	10,001
2.	29-08-2025	£0.10	2000

d) 

Aggregated information: 

· Aggregated volume 

· Price 

£0.20	10,001
£0.10	2000

e) 

Date of the transaction 

29/08/2025

f) 

Place of the Transaction 

Aquis Exchange Growth Market (AQSE) 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXSEMFMUEISEDA